Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation G Fabbri, S Rasi, D Rossi, V Trifonov, H Khiabanian, J Ma, A Grunn, ... Journal of Experimental Medicine 208 (7), 1389-1401, 2011 | 789 | 2011 |
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia D Rossi, S Rasi, V Spina, A Bruscaggin, S Monti, C Ciardullo, ... Blood, The Journal of the American Society of Hematology 121 (8), 1403-1412, 2013 | 600 | 2013 |
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia D Rossi, S Rasi, G Fabbri, V Spina, M Fangazio, F Forconi, R Marasca, ... Blood, The Journal of the American Society of Hematology 119 (2), 521-529, 2012 | 556 | 2012 |
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development D Rossi, V Trifonov, M Fangazio, A Bruscaggin, S Rasi, V Spina, S Monti, ... Journal of Experimental Medicine 209 (9), 1537-1551, 2012 | 421 | 2012 |
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation D Rossi, V Spina, C Deambrogi, S Rasi, L Laurenti, K Stamatopoulos, ... Blood, The Journal of the American Society of Hematology 117 (12), 3391-3401, 2011 | 419 | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. A Palumbo, M Cavo, S Bringhen, E Zamagni, A Romano, F Patriarca, ... Journal of Clinical Oncology 29, 986-993, 2011 | 390 | 2011 |
Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience D Vallisa, P Bernuzzi, L Arcaini, S Sacchi, V Callea, R Marasca, ... Journal of Clinical Oncology 23 (3), 468-471, 2005 | 319 | 2005 |
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome E Chigrinova, A Rinaldi, I Kwee, D Rossi, PMV Rancoita, JC Strefford, ... Blood, The Journal of the American Society of Hematology 122 (15), 2673-2682, 2013 | 279 | 2013 |
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia D Rossi, L Terzi-di-Bergamo, L De Paoli, M Cerri, G Ghilardi, A Chiarenza, ... Blood, The Journal of the American Society of Hematology 126 (16), 1921-1924, 2015 | 263 | 2015 |
NOTCH1 mutations in+ 12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis … I Del Giudice, D Rossi, S Chiaretti, M Marinelli, S Tavolaro, S Gabrielli, ... haematologica 97 (3), 437, 2012 | 262 | 2012 |
Bone marrow failure associated with human herpesvirus 8 infection after transplantation M Luppi, P Barozzi, TF Schulz, G Setti, K Staskus, R Trovato, F Narni, ... New England Journal of Medicine 343 (19), 1378-1385, 2000 | 260 | 2000 |
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials S Bringhen, MV Mateos, S Zweegman, A Larocca, AP Falcone, A Oriol, ... Haematologica 98 (6), 980, 2013 | 258 | 2013 |
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ... Leukemia 34 (9), 2354-2363, 2020 | 257 | 2020 |
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome D Rossi, V Spina, M Cerri, S Rasi, C Deambrogi, L De Paoli, L Laurenti, ... Clinical Cancer Research 15 (13), 4415-4422, 2009 | 251 | 2009 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple … A Palumbo, S Bringhen, A Larocca, D Rossi, F Di Raimondo, V Magarotto, ... Journal of Clinical Oncology 32 (7), 634-640, 2014 | 250 | 2014 |
Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of … M Thorsélius, A Kröber, F Murray, U Thunberg, G Tobin, A Bühler, ... Blood 107 (7), 2889-2894, 2006 | 244 | 2006 |
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma D Rossi, S Deaglio, D Dominguez-Sola, S Rasi, T Vaisitti, C Agostinelli, ... Blood, The Journal of the American Society of Hematology 118 (18), 4930-4934, 2011 | 235 | 2011 |
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM A Jakubowiak, M Offidani, B Pégourie, J De La Rubia, L Garderet, K Laribi, ... Blood, The Journal of the American Society of Hematology 127 (23), 2833-2840, 2016 | 233 | 2016 |
Three cases of human herpesvirus‐6 latent infection: Integration of viral genome in peripheral blood mononuclear cell DNA M Luppi, R Marasca, P Barozzi, S Ferrari, L Ceccherini‐Nelli, G Batoni, ... Journal of medical virology 40 (1), 44-52, 1993 | 232 | 1993 |
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome A Rinaldi, M Mian, E Chigrinova, L Arcaini, G Bhagat, U Novak, ... Blood, The Journal of the American Society of Hematology 117 (5), 1595-1604, 2011 | 208 | 2011 |